Astellas Pharma
Search results
Daiichi Sankyo is an innovative global healthcare company based in Japan underpinned by its Purpose: “To contribute to the enrichment of quality of life around the world”.
Daiichi Sankyo is an innovative global healthcare company based in Japan underpinned by its Purpose: “To contribute to the enrichment of quality of life around the world”.
Jun 26, 2024 · About Daiichi Sankyo Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology ...
6 days ago · The U.S. Food and Drug Administration declined to approve Merck and Japan-based Daiichi Sankyo's lung cancer treatment, which belongs to a lucrative class of cancer therapies that work like ...
6 days ago · On Wednesday, the FDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi Sankyo (OTC:DSKYF) (OTC:DSNKY) and Merck & Co Inc ...
Jun 27, 2024 · Daiichi Sankyo - a global pharmaceutical company Latest news and general information about the company, its affiliates and production plants as well as its main product portfolio. Passion for Innovation.
Jul 27, 2020 · Tokyo, Munich and Basking Ridge, NJ – (July 27, 2020) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has entered into a global development and commercialization agreement with AstraZeneca (LSE, STO, NYSE: AZN) for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC), currently ...
Jun 27, 2024 · The letter did not query the submitted efficacy or safety data for patritumab deruxtecan. Daiichi Sankyo research and development global head Ken Takeshita stated: “We will work closely with the FDA and the third-party manufacturer to address the feedback as quickly as possible in order to bring the first HER3-directed medicine to patients with previously-treated EGFR-mutated non-small cell ...
6 days ago · MSD and Daiichi Sankyo filed for approval of patritumab deruxtecan based on the 225-subject HERTHENA-Lung01 study, which showed an objective response rate (ORR) of 29.8% with the ADC, including ...
Daiichi Sankyo Company, Limited (Jepun: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) ialah syarikat farmaseutikal global dan syarikat farmaseutikal terbesar kedua di Jepun. Syarikat ini mencapai pendapatan JPY 2.305,4 bilion pada tahun 2018.
